Indeed, cancer cells hijack the CD47-SIRPα interaction by upregulating CD47 (13, 14) and blocking CD47 on cancer cells has been demonstrated to improve the efficacy of different therapeutic antibodies in inducing ADCP in several preclinical mouse models (15, 16). Here, SIRPA is linked to cancer.